Cholinesterase inhibitors: A patent review (2007 - 2011)

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 8, 2012, Pages 853-869

  De Los Ríos, Cristóbal ^a,b  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b INSTITUTO TEÓFILO HERNANDO   (Spain)

Author keywords

Acetylcholinesterase; Alzheimer s disease; Butyrylcholinesterase; Cholinesterase inhibitors; Donepezil; Galantamine; Gastrointestinal diseases; Inflammation; Multitarget strategy; Neostigmine; Rivastigmine; Tacrine

Indexed keywords

BETAHISTINE; BRIVARACETAM; CHOLINESTERASE INHIBITOR; DESIPRAMINE; DICLOFENAC; DIMEBON; DONEPEZIL; DUROTAK; ESCITALOPRAM; ETIRACETAM; GALANTAMINE; HUPERZINE A; LADOSTIGIL; MEMANTINE; MIANSERIN; NEOSTIGMINE; NORTRIPTYLINE; NOSCIRA; PHYSOSTIGMINE; PROMETHAZINE; PYRIDOSTIGMINE; RASAGILINE; RISPERIDONE; RIVASTIGMINE; SERTRALINE; TACRINE; TEGASEROD; TIDEGLUSIB; TRANYLCYPROMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSOLIC ACID;

ABDOMINAL DISTENSION; ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; DEPRESSION; DISEASE COURSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPEPSIA; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; HUMAN; HYDROLYSIS; IC 50; MEMORY; NAUSEA; NEUROPROTECTION; NONHUMAN; PATENT; POSTSYNAPTIC POTENTIAL; PRESBYOPIA; REVIEW; SIDE EFFECT; SLEEP DISORDER; STOMACH EMPTYING; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; WEIGHT REDUCTION;

ACETYLCHOLINE; ALZHEIMER DISEASE; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CHOLINESTERASE INHIBITORS; DRUG DESIGN; HUMANS; LEGISLATION, DRUG; MOLECULAR STRUCTURE; PATENTS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84864224510     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.701619     Document Type: Review

References (99)

1. Bourne Y, Grassi J, Bougis PE, et al. Conformational flexibility of the acetylcholinesterase tetramer suggested by x-ray crystallography. J Biol Chem 1999;274:30370-6
2. Ott P, Lustig A, Brodbeck U, et al. Acetylcholinesterase from human erythrocytes membranes: Dimers as functional units. FEBS Lett 1982;138:187-9
3. Liao J, Heider H, Sun MC, et al. Different glycosylation in acetylcholinesterases from mammalian brain and erythrocytes. J Neurochem 1992;58:1230-8
4. Atack JR, Yu QS, Soncrant TT, et al. Comparative inhibitory effects of various physostigmine analogs against acetyl- and butyrylcholinesterases. J Pharmacol Exp Ther 1989;249:194-202 (Pubitemid 19115808)
5. Buchwald P. Structure-metabolism relationships: Steric effects and the enzymatic hydrolysis of carboxylic esters. Mini Rev Med Chem 2001;1:101-11
6. Summers WK, Majovski LV, Marsh GM, et al. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, alzheimer type. N Engl J Med 1986;315:1241-5 (Pubitemid 17049681)
7. Summers WK, Viesselman JO, Marsh GM, et al. Use of tha in treatment of alzheimer-like dementia: Pilot study in twelve patients. Biol Psychiatry 1981;16:145-53 (Pubitemid 11186518)
8. Giacobini E. Invited review: Cholinesterase inhibitors for alzheimer's disease therapy: From tacrine to future applications. Neurochem Int 1998;32:413-19 (Pubitemid 28287193)
9. Marco-Contelles J, Rodriguez C, et al. Chemical synthesis of galantamine, an acetylcholinesterase inhibitor for treatment of alzheimers disease. Expert Opinion on Therapeutic Patents 2005;15:575-87 (Pubitemid 40711762)
10. 2+ regulators, a multitarget strategy for alzheimer's disease. Curr Top Med Chem 2011;11:2807-23
11. Brunton LLC, Knollman B. Goodman & gilman's the pharmacological basis of therapetics. McGrawHill; New York: 2011
12. Goedert M, Spillantini MG. A century of alzheimer's disease. Science 2006;314:777-81
13. Castro A, Martinez A. Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. Curr Pharm Des 2006;12:4377-87 (Pubitemid 44718295)
14. Gong CX, Iqbal K. Hyperphosphorylation of microtubule-associated protein tau: A promising therapeutic target for alzheimer disease. Curr Med Chem 2008;15:2321-8
15. Pratico D. Evidence of oxidative stress in alzheimer's disease brain and antioxidant therapy: lights and shadows. Ann N Y Acad Sci 2008;1147:70-8
16. Rafii MS, Aisen PS. Recent developments in alzheimer's disease therapeutics. BMC Med 2009;7:7
17. Fillit HM, Doody RS, Binaso K, et al. Recommendations for best practices in the treatment of alzheimer's disease in managed care. Am J Geriatr Pharmacother 2006;4(Suppl A):S9-S24; quiz S25-S28
18. O'Neill MF. Difficult times for alzheimer's treatments. Drug Discov Today 2005;10:1333-5
19. Li W, Mak M, Jiang H, et al. Novel anti-alzheimer's dimer bis(7)-cognitin: Cellular and molecular mechanisms of neuroprotection through multiple targets. Neurotherapeutics 2009;6:187-201
20. Arias E, Ales E, Gabilan NH, et al. Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: Involvement of nicotinic acetylcholine receptors. Neuropharmacology 2004;46:103-14 (Pubitemid 37494744)
21. Melo JB, Sousa C, Garcao P, et al. Galantamine protects against oxidative stress induced by amyloid-beta peptide in cortical neurons. Eur J Neurosci 2009;29:455-64
22. Noh MY, Koh SH, Kim Y, et al. Neuroprotective effects of donepezil through inhibition of gsk-3 activity in amyloid-beta-induced neuronal cell death. J Neurochem 2009;108:1116-25
23. Inestrosa NC, Alvarez A, Perez CA, et al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into alzheimer's fibrils: Possible role of the peripheral site of the enzyme. Neuron 1996;16:881-91 (Pubitemid 26124065)
24. Bartolini M, Bertucci C, Cavrini V, et al. Beta-amyloid aggregation induced by human acetylcholinesterase: Inhibition studies. Biochem Pharmacol 2003;65:407-16 (Pubitemid 36084557)
25. Espinoza-Fonseca LM. The benefits of the multi-target approach in drug design and discovery. Bioorg Med Chem 2006;14:896-7 (Pubitemid 43059780)
26. Camps P, Formosa X, Galdeano C, et al. Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation. J Med Chem 2008;51:3588-98 (Pubitemid 351875014)
27. Piazzi L, Cavalli A, Colizzi F, et al. Multi-target-directed coumarin derivatives: hache and bace1 inhibitors as potential anti-alzheimer compounds. Bioorg Med Chem Lett 2008;18:423-6
28. de Los Rios C, Egea J, Marco-Contelles J, et al. Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives. J Med Chem 2010;53:5129-43
29. Boschetti N, Liao J, Brodbeck U. The membrane form of acetylcholinesterase from rat brain contains a 20 kda hydrophobic anchor. Neurochem Res 1994;19:359-65 (Pubitemid 24054808)
30. Viegas CJ, Bolzani V, Lacerda-Barreiro ED, et al. Piperidinic derivatives, pharmaceutic compositions containing the same and preparation processes. US2007244137; 2007
31. Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors. WO2008073452; 2008
32. Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 2003;4:131-8 (Pubitemid 37271383)
33. MGP Biotechnologies, Inc. Butyrylcholinesterase inhibitors. WO2008055249; 2008
34. Universidad de Barcelona. Acetylcholinesterase-inhibiting compounds for treating alzheimer's disease. WO2007122274;2007
35. YISSUM Research Development Co. Use of low-dose ladostigil for neuroprotection. WO2007087029; 2007
36. Weinstock M, Bejar C, Wang RH, et al. Tv3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of alzheimer's disease. J Neural Transm Suppl 2000;157-69 (Pubitemid 32037191)
37. Gordon CJ.. Thermoregulation in laboratory mammals and humans exposed to anticholinesterase agents. Neurotoxicol Teratol 1994;16:427-53 (Pubitemid 24305379)
38. Colucid Pharmaceuticals, Inc. Compounds that inhibit cholinesterase. WO2008097546; 2008
39. Colucid Pharmaceuticals, Inc. Compositions of cholinesterase inhibitors. WO2010115124; 2010
40. Biotechnology Research Corp. Heterodimers and methods of using them. WO2008091901; 2008
41. Solvay Pharmaceuticals B.V. Compounds with a combination of cannabionoid-cb1 antagonism and acetylcholinesterase inhibition. WO2008074816; 2008
42. Wolff MC, Leander JD. Sr141716a, a cannabinoid cb1 receptor antagonist, improves memory in a delayed radial maze task. Eur J Pharmacol 2003;477:213-17 (Pubitemid 38366393)
43. Berger C, Schmid PC, Schabitz WR, et al. Massive accumulation of n-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia? J Neurochem 2004;88:1159-67 (Pubitemid 38280683)
44. Hikida T, Kitabatake Y, Pastan I, et al. Acetylcholine enhancement in the nucleus accumbens prevents addictive behaviors of cocaine and morphine. Proc Natl Acad Sci USA 2003;100:6169-73 (Pubitemid 36576949)
45. Cohen MJ, Jasser S, Herron PD, et al. Ethical perspectives: Opioid treatment of chronic pain in the context of addiction. Clin J Pain 2002;18:S99-107 (Pubitemid 34815400)
46. Consejo Superior de Investigaciones Cientificas. New derivatives of propargylamine having neuroprotective capacity for the treatment of alzheimer's and parkinson's diseases. WO2011113988; 2011
47. Alper G, Girgin FK, Ozgonul M, et al. Mao inhibitors and oxidant stress in aging brain tissue. Eur Neuropsychopharmacol 1999;9:247-52 (Pubitemid 29114931)
48. Bolea I, Juarez-Jimenez J, de Los Rios C, et al. Synthesis, biological evaluation, and molecular modeling of donepezil and n-[(5-(benzyloxy)-1-methyl- 1h-indol-2-yl) methyl]-n-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of alzheimer's disease. J Med Chem 2011;54:8251-70
49. Camps P, El Achab R, Morral J, et al. New tacrine-huperzine a hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of alzheimer's disease. J Med Chem 2000;43:4657-66
50. Universidad Autonoma de Madrid. 1,8-naphthyridine-derived compounds and the use thereof in the treatment of neurodegenerative diseases. WO2011051527; 2011
51. Sheppeck JE II, Gauss CM, Chamberlin AR. Inhibition of the ser-thr phosphatases pp1 and pp2a by naturally occurring toxins. Bioorg Med Chem 1997;5:1739-50 (Pubitemid 27423732)
52. Esteve SA. Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity. WO2007147883; 2007
53. Medivation, Inc. Methods and combinatioin therapies for treating alzheimer's disease. WO2008051599; 2008
54. Jones RW. Dimebon disappointment. Alzheimers Res Ther 2010;2:25
55. Adamas Pharmaceuticals, Inc. Treatment of mild dementia of the alzheimer's disease type. WO2009091932; 2009
56. Memory Pharmaceuticals Corp. Methods of treating alzheimer's disease with (+)-isopropyl 2-methoxyethyl-4-(2-chloro-3-cyanophenyl)-1,4-dihydro-2,6- dimethylpyridine-3,5-dicarboxylate and a cholinesterase inhibitor. WO2009051922; 2009
57. Tollefson GD. Short-term effects of the calcium channel blocker nimodipine (bay-e-9736) in the management of primary degenerative dementia. Biol Psychiatry 1990;27:1133-42 (Pubitemid 20150025)
58. Allergan, Inc. Compositions comprising a cholinesterase inhibitor for treating cognitive disorders. WO2011009061; 2011
59. Bush AI, Tanzi RE. Therapeutics for alzheimer's disease based on the metal hypothesis. Neurotherapeutics 2008;5:421-32 (Pubitemid 351952485)
60. Johns Hopkins University. Methods and compositions for improving cognitive function. WO2011100373; 2011
61. Bajjalieh SM, Peterson K, Shinghal R, et al. Sv2, a brain synaptic vesicle protein homologous to bacterial transporters. Science 1992;257:1271-3
62. Custer KL, Austin NS, Sullivan JM, et al. Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J Neurosci 2006;26:1303-13 (Pubitemid 43237062)
63. Noscira SA. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative. WO2011151359; 2011
64. Martinez A, Alonso M, Castro A, et al. First non-atp competitive glycogen synthase kinase 3 beta (gsk-3beta) inhibitors: Thiadiazolidinones (tdzd) as potential drugs for the treatment of alzheimer's disease. J Med Chem 2002;45:1292-9 (Pubitemid 34263565)
65. Northwestern University. Compositions and treatments using pyridazine compounds and cholinesterase inhibitors. WO2007127474; 2007
66. Schering Corp. Heterocyclic aspartyl protease inhibitors. WO2008103351; 2008
67. Epix Delaware, Inc. Combination comprising 5ht6 modulators and cholinesterase inhibitors. WO2008002539; 2008
68. Eisai R&D Management. Cinnamide compounds for dementia. WO2008139984; 2008
69. Auspex Pharmaceutical, Inc. Indanone inhibitors of acetylcholinesterase. WO2010077730; 2010
70. Novartis AG. Transdermal therapeutic system for the administration of rivastigmine. EP2292219; 2011
71. Pan BC. Huperzine a prodrugs and uses thereof. US20070082922; 2007
72. Galantos Pharma GMBH. Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment. WO2007039138; 2007
73. Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003;421:384-8 (Pubitemid 36157937)
74. Lauretti GR, Oliveira AP, Juliao MC, et al. Transdermal nitroglycerine enhances spinal neostigmine postoperative analgesia following gynecological surgery. Anesthesiology 2000;93:943-6
75. Nicolodi M, Galeotti N, Ghelardini C, et al. Central cholinergic challenging of migraine by testing second-generation anticholinesterase drugs. Headache 2002;42:596-602
76. Almeida RA, Lauretti GR, Mattos AL. Antinociceptive effect of low-dose intrathecal neostigmine combined with intrathecal morphine following gynecologic surgery. Anesthesiology 2003;98:495-8 (Pubitemid 36603342)
77. University of Medicine and Dentistry. Unique dual-action therapeutics. WO2010051044; 2010
78. Halen PK, Chagti KK, Giridhar R, et al. Combining anticholinergic and anti-inflammatory activities into a single moiety: A novel approach to reduce gastrointestinal toxicity of ibuprofen and ketoprofen. Chem Biol Drug Des 2007;70:450-5 (Pubitemid 47609959)
79. Horta-Lima CE. Pharmaceutical preparation containing an acetylcholinesterase inhibitor and an antidepressant with 5-ht and alpha-2-adrenoceptor blocking properties. WO2007012154; 2007
80. EISAI R&D Management Co., Ltd. Ampa receptor antagonists for neurophatic pain. WO2009011412; 2009
81. Kellerman GH, Bull MJ. Supporting acetylcholine function. US20110015154; 2011
82. Dokmeci D. Oxidative stress, male infertility and the role of carnitines. Folia Med (Plovdiv) 2005;47:26-30
83. Ponec RJ, Saunders MD, Kimmey MB. Neostigmine for the treatment of acute colonic pseudo-obstruction. N Engl J Med 1999;341:137-41 (Pubitemid 29325740)
84. Ghisalberti C. Medicament comprising terpenoid cholinesterase inhibitor for treatment of dismotility disorder. WO2010092467; 2010
85. Ghisalberti C. Composition comprising alginates and d-limonene to treat gerd and dyspepsia. WO2010092468; 2010
86. Novartis AG. Organic compounds. WO2007071394; 2007
87. Helsinn Therapeutics Method of stimulating the motility of the gastrointestinal system using ipamorelin. WO2009082426; 2009
88. Rao V, Spiro JR, Rosenberg PB, et al. An open-label study of escitalopram (lexapro) for the treatment of 'depression of alzheimer's disease' (dad). Int J Geriatr Psychiatry 2006;21:273-4
89. Mowla A, Mosavinasab M, Pani A. Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. J Clin Psychopharmacol 2007;27:67-70 (Pubitemid 46105768)
90. Eisai R&D Management Co. Novel combination of drugs as antidepressant. WO2007034990; 2007
91. Volvovitz F. Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction. US20080090808; 2008
92. Volvovitz F. Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction. US20090048234; 2009
93. Woolley ML, Waters KA, Reavill C, et al. Selective dopamine d4 receptor agonist (a-412997) improves cognitive performance and stimulates motor activity without influencing reward-related behaviour in rat. Behav Pharmacol 2008;19:765-76
94. BRC Operations Ltd. Method for formulating combination medications for adhd. WO2008083442; 2008
95. Colucid Pharmaceuticals. Methods for promoting wakefulness. WO2009011901; 2009
96. Kaufman HE. Preparations and methods for ameliorating or reducing presbyopia. WO2010135731; 2010
97. Schneider EB. Treatment and prevention of secondary injury after trauma or damage to the central nervous system. WO2011026060; 2011
98. Chelsea Therapeutics. Pharmaceutical compositions comprising droxidopa. WO2008003028; 2008
99. Chelsea Terapeutics. Droxidopa and pharmaceutical compositions thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders. WO2008137923; 2008